Axsome Therapeutics Announces Pricing of Initial Public Offering
NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Capital Market on November 19, 2015, under the symbol “AXSM.” The offering is expected to close on November 24, 2015, subject to customary closing conditions.
The sole book-running manager for the offering is Ladenburg Thalmann & Co. Inc. Cantor Fitzgerald & Co. is acting as lead manager and Brean Capital, LLC is acting as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 19, 2015. The offering is being made by means of a prospectus, copies of which may be obtained from Ladenburg Thalmann & Co. Inc., 570 Lexington Avenue, 11th Floor, New York, New York 10022, or by email at email@example.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders. By focusing on this therapeutic area, Axsome is addressing significant and growing markets where current treatment options are limited or inadequate. Axsome’s product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which are being developed for multiple indications. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.